FILTER
FILTERED INTERVIEW RESULTS
Peter Schiemann
CEO, YMMUNOBIO
"We are dedicated to establishing proof of concept with our ADC targeting NPTXR."
Krishna Kanumuri
CEO AND MANAGING DIRECTOR, SAI LIFE SCIENCES
"I anticipate a continued trend of Western companies exploring India as an attractive manufacturing destination."
Tim Tyson
CHAIRMAN AND CEO, TRIRX PHARMACEUTICALS
"Great innovations and new medicines are emerging in the animal health space, especially in terms of biologics and monoclonal antibodies, and we saw great opportunities in this developing area."
Mike Radomsky
CEO, CMC PHARMACEUTICALS
"As biotech companies secure funding and advance their drug development programs, the demand for our services is expected to increase."
Trevor Caswell
CHAIRMAN, PHARMA.AERO
"We now offer an open platform for life sciences companies to have conversations around priorities in their field and discuss challenges in the supply chain."
Anwar Daud
MANAGING DIRECTOR, ZIM LABORATORIES
"We progressed on the development of our New Innovative Products (NIP), which are complex generics developed using in-house proprietary technology platforms."
Daniel Prince
CEO, PRINCE STERILIZATION SERVICES
"We are extremely excited about the growth our hydrogen peroxide and packaging segments can bring."
Joe Panetta
PRESIDENT AND CEO, BIOCOM CALIFORNIA
"We are beginning to see California move forward as not two or three individual clusters, but rather as a powerhouse of integrated clusters, and this will continue to be our focus in the future."
Kendalle Burlin O’Connell
CEO AND PRESIDENT, MASSBIO
"In 2023, Massachusetts made up just shy of 15% of the national drug development pipeline and approximately 7% of the global drug development pipeline."
Andrea Confetti and Roberto Fanelli
EXCLUSIVE SYNTHESIS BU LEADER (AC) & CATALOGUE APIS BU LEADER (RF), DIPHARMA FRANCIS
"Dipharma is proud to have been reliably serving the life sciences industry for decades and will continue to do so for many years to come."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2024 - Digital Interactive
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
